Innovative clinical trials that enhance the understanding of cardiovascular disease and improve the care of patients.


Since its inception in 1984, the TIMI Study Group has been an Academic Research Organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. We have led a wide array of trials, from phase I to phase IV, enrolling from less than 30 to more than 26,000 subjects, and with both industry and NIH support. Trials have been conducted in over 50 countries and at more than 5000 separate sites.

We investigate a broad array of therapeutic interventions in individuals across the spectrum of cardiovascular disease, ranging from prevention in those with risk factors, to emergent interventions in those with acute manifestations of disease. In addition, we have used our large database of clinical findings, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors.

By leading large-scale, international, randomized controlled trials of novel therapeutics and performing sophisticated analyses, we have been privileged to help shape the very practice of cardiovascular medicine for over a quarter of a century.


Academic Trial Leadership

TIMI Study Group investigators provide leadership for clinical trial design, execution, and analysis

Global Trial Operations

Global Trial Management, Biostatistics, Clinical Events Committee, Safety Desk, Medical Hotline

Core Labs

Biomarkers, Proteomics, Metabolomics, Genomics, ECG


Practice-changing contributions to the medical literature

Current and Recent Trials

Recent News and Publications

1/23/2018 - New Publication: Bonaca et al., Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial . Circ 2018.

12/5/2017 - New Publication: Sabatine et al., Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017.

12/1/2018 - New Publication: Giugliano et al., Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cards 2017 .

11/30/2018 - New Publication: Cavallari et al., Frequency, Predictors and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients with Symptomatic Atherosclerosis. Circ 2017.

 More News